Nathaniel Erdmann is an Infectious Disease physician affiliated with University of Alabama at Birmingham. OpenAlex indexes 41 publications with 3,097 citations (h-index 18).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingMedicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
40.2%Statin11.1%Atorvastatin Calcium54%Rosuvastatin Calcium46%Part D<11 patientsCalcium channel blocker7.6%Amlodipine Besylate100%Part D<11 patients+ 6 more classes in this area
Nervous system
18.2%Gabapentinoids6.3%Gabapentin100%Part D<11 patientsSSRI5.1%Fluoxetine Hcl58%Trazodone Hcl42%Part D<11 patients+ 3 more classes in this area
Anti-infectives
10.4%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor6.4%Tivicay54%Juluca46%Part D<11 patientsShort-acting sulfonamides2%Sulfamethoxazole-Trimethoprim100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2017–2022 per NIH RePORTER. The latest:
- Tissue and organ specific human B cell immunity: Supplement - Metabolic Risk Factors and Inflammation in PASC Development
University of Alabama at Birmingham
FY2022$1,033,284U19AI142737 - Viral adaptation to CD4 T cell responses and the impact on HIV immunity
University of Alabama at Birmingham
FY2021$149,019K08AI129705 - Viral adaptation to CD4 T cell responses and the impact on HIV immunity
University of Alabama at Birmingham
FY2020$195,264K08AI129705
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Vera Bittner
University of Alabama at Birmingham
David Standaert, MD, PhD
University of Alabama at Birmingham
Erik Roberson
University of Alabama at Birmingham
Bruce Korf
University of Alabama at Birmingham
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”